Outcomes of the first-in-human study with a recombinant botulinum toxin type E (rBoNT-E): Safety and pharmacodynamic profile of rBoNT-E compared with abobotulinumtoxinA (Dysport®)
- Resource Type
- Abstract
- Source
- In
Toxicon December 2018 156 Supplement 1:S93-S93 - Subject
- Language
- ISSN
- 0041-0101